Ultivue: Richard Malabre

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Richard Malabre as CFO. Malabre most recently was vice president and controller at Oxford Immunotec, which was acquired this year by PerkinElmer. Prior to Oxford Immunotec, he held the position of controller and other senior financial roles at firms including Salient Surgical Technologies, Neurometrix, and Teradyne.